Shirley Michelle Shiller, DO

Articles

Evolution in the Field of HR+ Breast Cancer Management

March 16th 2023

Closing out their discussion on HR+ breast cancer management, expert panelists share their excitement for the evolving treatment paradigm.

Other Treatment Modalities for HR+ Metastatic Breast Cancer

March 9th 2023

Comprehensive discussion on novel treatment modalities in HR+ metastatic breast cancer and insight to when it is appropriate to select these agents.

HR+ Metastatic Breast Cancer: Optimal Selection of Endocrine Partners

March 9th 2023

Shared insight on the selection of endocrine partners while managing patients in the relapsed/refractory setting of HR+ metastatic breast cancer.

Advice for Community Physicians on Managing HER2+ Breast Cancer

March 7th 2023

Closing out their review on treatment strategies for HER2-expressing breast cancer, panelists share practical advice for the community setting.

Continuing CDK4/6 Inhibition at Progression of HR+ Metastatic Breast Cancer

March 2nd 2023

Key opinion leaders consider when it is appropriate to continue CDK4/6 inhibition at progression of disease in the setting of HR+ metastatic breast cancer.

Molecular Testing in Relapsed/Refractory HR+ Metastatic Breast Cancer

March 2nd 2023

A brief review of the role molecular profiling plays at a patient’s relapse with HR+ metastatic breast cancer.

Potential Role for T-DXd in Early-Stage HER2-Low Breast Cancer

February 28th 2023

Panelists share a brief discussion on early-stage HER2-low breast cancer and identify treatment options available in that setting.

Optimizing Real-World Management of HER2-Low Breast Cancer

February 28th 2023

Comprehensive insight on evolving management strategies for patients diagnosed with HER2-low breast cancer.

Factors in Selecting 1L Therapy for Patients With HR+ Metastatic Breast Cancer

February 23rd 2023

Expert perspectives on factors that aid in the selection of optimal first-line therapy for patients with HR+ metastatic breast cancer.

HR+ Metastatic Breast Cancer: Molecular Profiling and 1L Treatment Approaches

February 23rd 2023

Shifting their focus to HR+ metastatic disease, expert panelists consider the importance of molecular profiling and first-line treatment options.

Expert Perspectives on Defining HER2-Low Breast Cancer

February 21st 2023

Centered discussion on the advent of HER2-low breast cancer and how it is differentiated from HER2+ and HER2- disease.

Overview on Treatment Options for HER2+ Breast Cancer

February 21st 2023

Expert panelists provide a broad overview on HER2+ breast cancer and review the evolving treatment armamentarium.

How Clinical Trials Inform Treatment Selection in Early-Stage HR+ Breast Cancer

February 16th 2023

A brief review of prevalent clinical trials in the early-stage HR+ breast cancer paradigm and how they help to inform treatment decision-making.

Early-Stage HR+ Breast Cancer: Ki67 and the monarchE Trial

February 16th 2023

Key opinion leaders in breast cancer management discuss Ki67 and the monarchE trial, which analyzed abemaciclib therapy in the HR+ space.

How Ki67 Informs Use of Therapy in Early-Stage HR+ Breast Cancer

February 9th 2023

A broad look at the role of Ki67 expression in informing the selection of therapy for patients with early-stage HR+ breast cancer.

Best Practices for Molecular Testing in Early-Stage Breast Cancer

February 9th 2023

Expert panelists share their perspectives on best practices for molecular profiling in patients diagnosed with early-stage breast cancer.

Dr. Shiller on the Role of Trastuzumab Deruxtecan in HER2+ Breast Cancer

December 23rd 2022

Michelle Shiller, DO, AP/CP, MGP, discusses the role of trastuzumab deruxtecan in patients with HER2-positive breast cancer.

Dr. Shiller on Molecular Diagnostics in Gastrointestinal Cancers

October 23rd 2018

Shirley Michelle Shiller, DO, member of the Precision Medicine Institute's Advisory Committee, Baylor University Medical Center, discusses molecular diagnostics in gastrointestinal (GI) cancers.

Dr. Shiller on Next-Generation Sequencing in GI Cancers

September 20th 2018

Shirley Michelle Shiller, DO, member of the Precision Medicine Institute's Advisory Committee, Baylor University Medical Center, discusses next-generation sequencing in gastrointestinal malignancies.

Dr. Shiller on Hereditary Predisposition to Cancer

August 30th 2018

Shirley Michelle Shiller, DO, member of the Precision Medicine Institute's Advisory Committee, Baylor University Medical Center, discusses a patient’s hereditary predisposition to cancer.